Impact Biomedical (IBO) Asset Utilization Ratio (2025 - 2026)

Impact Biomedical's (IBO) quarterly Asset Utilization Ratio came in at 0.0 in Q1 2026, up 38.31% on a QoQ basis from 0.0 in Q3 2025.

Impact Biomedical (IBO) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 2 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	86.33 Bn	78.34 Bn	3.93 Bn	0.38
3	Argenx Se	65.13 Bn	59.95 Bn	1.37 Bn	-
4	Moderna	60.47 Bn	55.33 Bn	52.00 Mn	0.20
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.04 Bn	27.73 Bn	992.69 Mn	0.90
7	BioNTech SE	28.48 Bn	10.09 Bn	668.28 Mn	0.13
8	Insmed	27.36 Bn	26.20 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.23 Bn	26.39 Bn	-	0.13
10	Impact Biomedical	47.26 Mn	47.25 Mn	2,000.00	0.00

Download Data